Aseel Alftayeh
Worcester, MANPI 1972236693
Payments from drug & device makers
$2,066in general payments, 2019–2025
Across 91 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$494
- Novo Nordisk$180
- AstraZeneca$159
- E.r. Squibb & Sons, L.L.C.$157
- Gilead$146
- Alnylam Pharmaceuticals Inc.$146
- plus $785 from 15 others
What the payments were for
- Food & beverage$2,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $494 |
| Novo Nordisk | 6 | $180 |
| AstraZeneca(2 entities) | 8 | $159 |
| E.r. Squibb & Sons, L.L.C. | 11 | $157 |
| Gilead | 5 | $146 |
| Alnylam Pharmaceuticals Inc. | 7 | $146 |
| Bayer | 6 | $117 |
| Grifols USA, LLC | 4 | $116 |
| GSK | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $111 |
| Fresenius Kabi USA, LLC | 5 | $110 |
| Alcresta Therapeutics, Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Pfizer | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.